Shopping Cart 0
Cart Subtotal
USD 0

Actinium Pharmaceuticals Inc (ATNM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Actinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures Inc is a biopharmaceutical company that provides development of cancer immunotherapies. The company provides pipeline products such as Iomab-B that is used for hematopoietic stem cells transplantation. It provides Iomab-B through the monoclonal antibody BC8 that targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. ATNM provides mab expension and biobetters development in stratergical platform. It offers other pipeline products such as actimab-A for treatment of acute myeloid leukemia; actimab-C for colon cancer and actimab-P for the treatment of prostate cancer. The company uses alpha particle immunotherapy platform technology for drug development. ATNM is headquartered in New York, the US.

Actinium Pharmaceuticals Inc (ATNM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Actinium Pharma Raises USD 5 Million In First Closing Of Venture Financing Round 11

Partnerships 12

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12

Actinium Pharma Partners with Vector Oncology 13

Actinium Pharma Enters into Agreement with Medpace 14

Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15

Licensing Agreements 16

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16

Equity Offering 18

Actinium Pharma Prices Rights Offering of Units for USD25 Million 18

Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20

Actinium Pharma Raises USD10 Million in Public Offering of Shares 22

Actinium Pharma Raises USD5 Million in Private Placement of Shares 24

Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26

Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28

Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For USD 3.3 Million 30

Actinium Pharma Completes Private Placement Of Shares For USD 3.5 Million Upon Exercise Of Warrants 31

Actinium Pharma Plans IPO 32

Acquisition 33

Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33

Actinium Pharmaceuticals Inc-Key Competitors 34

Actinium Pharmaceuticals Inc-Key Employees 35

Actinium Pharmaceuticals Inc-Locations And Subsidiaries 36

Head Office 36

Recent Developments 37

Corporate Communications 37

May 01, 2018: Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors 37

Feb 08, 2018: Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation 38

Jan 08, 2018: Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company's AWE Technology Platform and Research Programs 39

Jun 09, 2017: Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer 40

Mar 28, 2017: Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company's Board of Directors 41

Jan 18, 2017: Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer 42

Product News 44

12/11/2017: Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M 44

Nov 14, 2017: Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform 45

Oct 01, 2018: Actinium launches Iomab-ACT program offering its targeted chemo-free lymphodepletion technology as a universal solution to CAR-T product developers 47

Clinical Trials 48

Sep 13, 2017: Actinium Pharmaceuticals Highlights on Actimab-M at the Society of Hematologic Oncology 2017 Annual Meeting 48

Feb 13, 2017: Actinium Pharmaceuticals' Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma 49

Feb 07, 2017: Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma 50

Other Significant Developments 51

Jan 25, 2018: Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 51

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Actinium Pharma Raises USD 5 Million In First Closing Of Venture Financing Round 11

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12

Actinium Pharma Partners with Vector Oncology 13

Actinium Pharma Enters into Agreement with Medpace 14

Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16

Actinium Pharma Prices Rights Offering of Units for USD25 Million 18

Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20

Actinium Pharma Raises USD10 Million in Public Offering of Shares 22

Actinium Pharma Raises USD5 Million in Private Placement of Shares 24

Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26

Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28

Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For USD 3.3 Million 30

Actinium Pharma Completes Private Placement Of Shares For USD 3.5 Million Upon Exercise Of Warrants 31

Actinium Pharma Plans IPO 32

Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33

Actinium Pharmaceuticals Inc, Key Competitors 34

Actinium Pharmaceuticals Inc, Key Employees 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Actinium Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Actinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures Inc is a biopharmaceutical company that provides development of cancer immunotherapies. The company provides pipeline products such as Iomab-B that is used for hematopoietic stem cells transplantation. It provides Iomab-B through the monoclonal antibody BC8 that targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. ATNM provides mab expension and biobetters development in stratergical platform. It offers other pipeline products such as actimab-A for treatment of acute myeloid leukemia; actimab-C for colon cancer and actimab-P for the treatment of prostate cancer. The company uses alpha particle immunotherapy platform technology for drug development. ATNM is headquartered in New York, the US.

Actinium Pharmaceuticals Inc (ATNM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Actinium Pharma Raises USD 5 Million In First Closing Of Venture Financing Round 11

Partnerships 12

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12

Actinium Pharma Partners with Vector Oncology 13

Actinium Pharma Enters into Agreement with Medpace 14

Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15

Licensing Agreements 16

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16

Equity Offering 18

Actinium Pharma Prices Rights Offering of Units for USD25 Million 18

Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20

Actinium Pharma Raises USD10 Million in Public Offering of Shares 22

Actinium Pharma Raises USD5 Million in Private Placement of Shares 24

Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26

Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28

Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For USD 3.3 Million 30

Actinium Pharma Completes Private Placement Of Shares For USD 3.5 Million Upon Exercise Of Warrants 31

Actinium Pharma Plans IPO 32

Acquisition 33

Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33

Actinium Pharmaceuticals Inc-Key Competitors 34

Actinium Pharmaceuticals Inc-Key Employees 35

Actinium Pharmaceuticals Inc-Locations And Subsidiaries 36

Head Office 36

Recent Developments 37

Corporate Communications 37

May 01, 2018: Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors 37

Feb 08, 2018: Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation 38

Jan 08, 2018: Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company's AWE Technology Platform and Research Programs 39

Jun 09, 2017: Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer 40

Mar 28, 2017: Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company's Board of Directors 41

Jan 18, 2017: Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer 42

Product News 44

12/11/2017: Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M 44

Nov 14, 2017: Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform 45

Oct 01, 2018: Actinium launches Iomab-ACT program offering its targeted chemo-free lymphodepletion technology as a universal solution to CAR-T product developers 47

Clinical Trials 48

Sep 13, 2017: Actinium Pharmaceuticals Highlights on Actimab-M at the Society of Hematologic Oncology 2017 Annual Meeting 48

Feb 13, 2017: Actinium Pharmaceuticals' Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma 49

Feb 07, 2017: Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma 50

Other Significant Developments 51

Jan 25, 2018: Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 51

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actinium Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Actinium Pharma Raises USD 5 Million In First Closing Of Venture Financing Round 11

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12

Actinium Pharma Partners with Vector Oncology 13

Actinium Pharma Enters into Agreement with Medpace 14

Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16

Actinium Pharma Prices Rights Offering of Units for USD25 Million 18

Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20

Actinium Pharma Raises USD10 Million in Public Offering of Shares 22

Actinium Pharma Raises USD5 Million in Private Placement of Shares 24

Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26

Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28

Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For USD 3.3 Million 30

Actinium Pharma Completes Private Placement Of Shares For USD 3.5 Million Upon Exercise Of Warrants 31

Actinium Pharma Plans IPO 32

Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33

Actinium Pharmaceuticals Inc, Key Competitors 34

Actinium Pharmaceuticals Inc, Key Employees 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Actinium Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.